136 related articles for article (PubMed ID: 26987347)
1. Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.
Briggs AH; Parfrey PS; Khan N; Tseng S; Dehmel B; Kubo Y; Chertow GM; Belozeroff V
Med Decis Making; 2016 Nov; 36(8):965-72. PubMed ID: 26987347
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
Belozeroff V; Chertow GM; Graham CN; Dehmel B; Parfrey PS; Briggs AH
Value Health; 2015 Dec; 18(8):1079-87. PubMed ID: 26686794
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
4. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
[TBL] [Abstract][Full Text] [Related]
6. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet and Clinical Outcomes in Dialysis.
Komaba H; Fukagawa M
Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
[TBL] [Abstract][Full Text] [Related]
8. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
9. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
10. The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
Chang TI; Abdalla S; London GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; Mahaffey KW; Moe SM; Parfrey PS; Wheeler DC; Dehmel B; Goodman WG; Chertow GM
J Hum Hypertens; 2016 Mar; 30(3):204-9. PubMed ID: 26040438
[TBL] [Abstract][Full Text] [Related]
11. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
12. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
14. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
[TBL] [Abstract][Full Text] [Related]
15. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
[TBL] [Abstract][Full Text] [Related]
16. Etelcalcetide for the treatment of secondary hyperparathyroidism.
Hamano N; Komaba H; Fukagawa M
Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
[TBL] [Abstract][Full Text] [Related]
17. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
18. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
19. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
[TBL] [Abstract][Full Text] [Related]
20. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
Iannazzo S; Carsi M; Chiroli S
Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
